PureTech Health plc (LON:PRTC - Get Free Report)'s share price was up 6.3% during mid-day trading on Monday . The company traded as high as GBX 127 ($1.69) and last traded at GBX 125.40 ($1.67). Approximately 1,234,305 shares changed hands during trading, an increase of 17% from the average daily volume of 1,059,029 shares. The stock had previously closed at GBX 118 ($1.57).
PureTech Health Trading Up 0.8 %
The company has a market cap of £370.67 million, a price-to-earnings ratio of -5.06 and a beta of 1.02. The firm has a fifty day moving average price of GBX 133.04 and a 200 day moving average price of GBX 147.24. The company has a debt-to-equity ratio of 45.82, a quick ratio of 2.51 and a current ratio of 3.68.
PureTech Health Company Profile
(
Get Free Report)
PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.
See Also
Before you consider PureTech Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PureTech Health wasn't on the list.
While PureTech Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
